home / stock / cerc / cerc quote
Last: | $2.93 |
---|---|
Change Percent: | -1.68% |
Open: | $2.98 |
Close: | $2.93 |
High: | $2.98 |
Low: | $2.9 |
Volume: | 266,862 |
Last Trade Date Time: | 08/25/2021 04:41:35 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.93 | $2.98 | $2.93 | $2.98 | $2.9 | 266,862 | 08-25-2021 |
$2.98 | $2.88 | $2.98 | $3 | $2.88 | 401,043 | 08-24-2021 |
$2.89 | $2.82 | $2.89 | $2.93 | $2.7711 | 256,800 | 08-23-2021 |
$2.77 | $2.62 | $2.77 | $2.83 | $2.62 | 376,450 | 08-20-2021 |
$2.65 | $2.8 | $2.65 | $2.8893 | $2.61 | 419,575 | 08-19-2021 |
$2.78 | $2.79 | $2.78 | $2.87 | $2.72 | 207,544 | 08-18-2021 |
$2.79 | $2.73 | $2.79 | $2.81 | $2.6899 | 272,871 | 08-17-2021 |
$2.77 | $2.84 | $2.77 | $2.87 | $2.66 | 421,880 | 08-16-2021 |
$2.87 | $2.92 | $2.87 | $2.9626 | $2.86 | 392,057 | 08-13-2021 |
$2.93 | $3.02 | $2.93 | $3.03 | $2.9 | 407,562 | 08-12-2021 |
$3.06 | $2.96 | $3.06 | $3.06 | $2.88 | 472,972 | 08-11-2021 |
$2.96 | $2.98 | $2.96 | $3.1 | $2.95 | 339,852 | 08-10-2021 |
$3.02 | $2.88 | $3.02 | $3.05 | $2.8302 | 532,098 | 08-09-2021 |
$2.82 | $2.82 | $2.82 | $2.89 | $2.74 | 472,857 | 08-06-2021 |
$2.82 | $2.66 | $2.82 | $2.82 | $2.66 | 404,827 | 08-05-2021 |
$2.68 | $2.67 | $2.68 | $2.76 | $2.61 | 537,893 | 08-04-2021 |
$2.69 | $2.66 | $2.69 | $2.73 | $2.63 | 341,825 | 08-03-2021 |
$2.69 | $2.66 | $2.69 | $2.7899 | $2.65 | 320,474 | 08-02-2021 |
$2.66 | $2.68 | $2.66 | $2.72 | $2.64 | 351,724 | 07-30-2021 |
$2.69 | $2.75 | $2.69 | $2.805 | $2.69 | 301,825 | 07-29-2021 |
News, Short Squeeze, Breakout and More Instantly...
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeut...
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financ...
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-00...